Skip to content
Medical Health Aged Care

**UNDER EMBARGO UNTIL 4am AEST 2023, 7 September** Australian clinical study finds medicinal cannabis significantly improves pain, quality of life, fatigue, moderate-severe anxiety and depression

Little Green Pharma (ASX: LGP) 4 mins read


  • The Quality of Life Evaluation Study (QUEST Initiative) is one of the world’s largest longitudinal clinical studies investigating the effect of medicinal cannabis on patient quality of life
  • Analysis of 3-month follow-up results from 2,327 Australian patients participating in the QUEST Initiative show:
    • Very strong evidence of clinically meaningful improvements for those suffering health-related quality of life (HRQL) and fatigue
    • Clinically meaningful reductions in pain and significant improvements for moderate-severe anxiety and depression
  • • Peer reviewed findings available tomorrow in open-access journal PLOS ONE: [
  • Analysis of 12-month results underway assessing whether improvements are maintained over the longer term
  • Further studies regarding use of medicinal cannabis to alleviate sleep disorders
  • DropBox available with interviews, radio grabs and cultivation facility footage, see: 

Little Green Pharma (ASX: LGP) is pleased to advise analysis of initial results from the award-winning QUEST Initiative has found significant improvements in overall HRQL, fatigue levels as well as improvements in anxiety, depression and pain among Australian patients who have been part of the medicinal cannabis study during the initial three-month period.

The QUEST Initiative, sponsored by LGP, was one of the world’s largest longitudinal clinical studies investigating the effect of medicinal cannabis on patient quality of life and health economic impacts. The study was led by the University of Sydney with LGP exclusively supplying the medicinal cannabis products to patients enrolled in the study.

The study was also supported by not-for-profit private health insurance provider Health Insurance Fund of Australia (HIF) and guided by an experienced advisory group and endorsed by a range of national bodies, such as MS research Australia, Chronic Pain Australia, Arthritis Australia and Epilepsy Australia.


Adult patients in Australia who were newly prescribed medicinal cannabis for health conditions – including chronic pain, fatigue, sleep, depression and anxiety – between November 2020 and December 2021 were invited to participate in the study.

Participants completed a questionnaire before starting medicinal cannabis treatment and then subsequent questionnaires two weeks after commencing treatment, and every 1 – 2 months thereafter for up to one year.

Overall, 2,327 Australian patients aged between 18 to 97 years (average 51 years) participated in the study of which 63% of overall participants were female. Patients were recruited across six states by 120 independent doctors, a point of difference to the study.

The most-reported conditions being treated were chronic pain (69%); sleep disorders (23%); anxiety (22%); and anxiety/depression (11%); half of patients were being treated for more than one condition.


Results from the first three-months of patients using medicinal cannabis found there was very strong evidence (p<0.001) of clinically meaningful improvements in HRQL and fatigue across all health conditions assessed.

"Clinically meaningful results" in a study refer to findings that have a significant and important impact on a person's health or well-being. These results are not just small or insignificant changes; instead, they are substantial and can make a real difference in how healthcare professionals understand or treat a medical condition.

Patients also reported clinically meaningful reductions in pain and significant improvements for moderate-severe anxiety and depression.

However, three-month results for those patients assessed for sleep disorders found no change despite the very strong evidence of statistical improvement in feelings of fatigue. It is worth noting that these findings reflect the grouping of all medicinal cannabis oil formulations used by participants and that further analysis of the 12-month findings will seek to identify whether specific product formulations had differing impact on sleep.

These outcomes hold substantial clinical significance, particularly given the strict eligibility criteria for medicinal cannabis prescription in Australia, where patients must have exhausted conventional treatment options. It is remarkable for a single medication to exhibit a positive impact on treatment-resistant patients across such a broad range of medical conditions.

Dr. Jamie Rickcord, an independent General Practitioner involved in the QUEST Initiative, stated:

“The QUEST results show that medicinal cannabis provides statistically, and more importantly, clinically significant improvements in pain levels, fatigue and quality of life for patients. Doctors can have confidence in offering medicinal cannabis treatment as an option to those who qualify for it as result of emerging real-world data provided by initiatives such as QUEST”.

Next steps

Analysis of 12-month results is currently being undertaken to see if improvements are maintained over the longer term. In addition, further studies will be undertaken in relation to use of medicinal cannabis to alleviate sleep disorders.

Commenting on the three-month findings, Little Green Pharma Head of Research & Innovation Dr Leon Warne said:

“Little Green Pharma is extremely proud to support this significant study into the effect of medicinal cannabis on patient quality of life.

“These initial results are highly encouraging, highlighting meaningful improvements in health-related quality of life and fatigue levels as well as improvements to health conditions associated with anxiety, depression and pain among Australian patients who participated in the study. “As well as the medical benefits to patients, this study was able to provide access to experienced prescribers and more affordable medication.

“We now look forward to what the 12-month results show in terms of longer-term impact of medicinal cannabis on QUEST patients.”

Results from The QUEST Initiative comes after the recent launch of the new QUEST Global study led by another Australian university and sponsored by Little Green Pharma and HIF, to assess whether medicinal cannabis reduces the economic impact of chronic disease by reducing both the number of medications a patient requires and their need for healthcare services.

In 2020, HIF became the first major Australian health fund to declare support for access to medicinal cannabis treatments and research in Australia.

HIF CEO Justin James said studies like the QUEST Initiative provide insights that are valuable not just for HIF and its members but the health insurance industry as a whole.

“We are always interested in supporting studies into the health effectiveness of medicinal cannabis,” Mr James said. “They allow us to gain more information about the effectiveness of using medicinal cannabis to treat chronic conditions and how we can make these types of medications more economical going forward.”

Mr James said he was encouraged by the three-month findings from the QUEST Initiative and was looking forward to the 12-month results and understanding whether improvements are maintained over the longer term.

HIF has also pledged its support for the next phase of the study, QUEST Global.

“HIF proudly provides choice to members so they can have the flexibility to control their own medical outcomes,” he said. “Supporting members with medicinal cannabis as a treatment option is another choice that we are proud to provide members. “HIF members will once again have priority access to QUEST Global as participants, provided they meet the eligibility criteria.” 

About us:

For media enquiries / interview requests:

David Tasker, Chapter One Advisors

E:  M: 0433 112 936 


More from this category

  • Medical Health Aged Care
  • 29/05/2024
  • 17:07
JJP Biologics

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

JJP Biologics has received a positive conclusion on the Clinical Trial Application assessment for a Phase I Study of a potential first-in-class anti-CD89 antagonist,…

  • Contains:
  • Medical Health Aged Care
  • 29/05/2024
  • 11:54

Long-term prescription opioid use after hospital declining: study

UNSW Sydney medical researchers have shed light on post-hospital prescription opioid use. A large, linked data study has detailed the scale of prescription opioid…

  • Contains:
  • Medical Health Aged Care
  • 29/05/2024
  • 11:45
Cleo Diagnostics Limited ASX.COV

Cleo’s Ovarian Cancer Blood Test Outperforms Current Clinical Benchmark

Highlights A benchmarking study comparing CLEO’s ovarian cancer blood test against ultrasound has been published in scientific journal “Cancers” The study confirmed that CLEO’s initial test for the surgical triage market:– Significantly outperforms current clinical workflows that use CA125 and ultrasound to predict malignancy;– Correctly detected 90% of early-stage cancers compared to only 50% using standard workflows; and– Can be easily adopted for use into clinical practice. The superior performance of CLEO’s test now compared to all current routine clinical tools shows the significant global potential for the test in clinical decision making prior to surgical intervention. MELBOURNE, AUSTRALIA, 29…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.